skip to main
|
skip to sidebar
Blog Archives: Nov 2004 - present
Special items: Ovarian Cancer and Us blog best viewed in Firefox
Abstract
The poly (ADP-ribose) polymerase (PARP) family of enzymes is important
in several DNA repair pathways. Drugs that inhibit these enzymes have
been investigated in many types of cancer, but their application in the
treatment of gynecologic malignancies has rapidly evolved - as
manifested by the 2014 FDA approval for olaparib in the treatment of
recurrent ovarian cancer associated with a germline BRCA mutation
(gBRCA). In efforts to broaden their efficacy, current clinical trials
have demonstrated benefit of olaparib, and other PARP inhibitors
(PARPi), as single agents and in combination with cytotoxic chemotherapy
and biologic agents, in wide ranging populations. Although the majority
of data for PARPi in gynecologic malignancies has been specifically
regarding ovarian cancer, their role in the treatment of uterine and
cervical cancer is currently being investigated. This review will serve
as a synopsis of seminal trials to date, summarize the breadth of
clinical application in on-going studies, query how these results may
change future practice, and reflect on questions yet to be answered.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.